A benzodifuranone dye carrying at least one thiazolyl group, the dye may be of Formula (3) or Formula (5):
in which
Ris -H or alkyl;
Xis -H, alkyl or alkylcarbonyl;
Ais a phenyl group which is unsubstituted by from one to three substituents or
Ais a group of Formula (4):
wherein:
R¹is -H or alkyl; and
X¹is -H, alkyl or alkylcarbonyl.
The benzodifuranone dyes are useful for the coloration of synthetic textile material such as polyester.
Phenethylthiazolethiourea (PETT) Compounds, a New Class of HIV-1 Reverse Transcriptase Inhibitors. 1. Synthesis and Basic Structure-Activity Relationship Studies of PETT Analogs
作者:Frank W. Bell、Amanda S. Cantrell、Marita Hoegberg、S. Richard Jaskunas、Nils Gunnar Johansson、Christopher L. Jordan、Michael D. Kinnick、Peter Lind、John M. Morin
DOI:10.1021/jm00025a010
日期:1995.12
of potent specific HIV-1 inhibitory compounds is described. The lead compound in the series, N-(2-phenethyl)-N'-(2-thiazolyl)thiourea (1), inhibitsHIV-1 RT using rCdG as the template with an IC50 of 0.9 microM. In MT-4 cells, compound 1 inhibitsHIV-1 with an ED50 of 1.3 microM. The 50% cytotoxic dose in cell culture is > 380 microM. The chemical structure-activityrelationship (SAR) was developed
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
申请人:——
公开号:US20030176476A1
公开(公告)日:2003-09-18
The present invention relates to compounds with the formula (I) and also to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-&bgr;-hydroxysteroid dehydrogenase type 1 enzyme.
Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
申请人:Biovitrum AB
公开号:US07125900B2
公开(公告)日:2006-10-24
The present invention relates to compounds with the formula (I) and also to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme.
The present invention provides a compound represented by the following general formula (I):
or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and/or diabetic nephropathy and the like.